title: [How I treat ... basal cell carcinoma by imiquimod].
abstract: Basal cell carcinoma is the most frequent cancer in humans. Several clinical types are distinguished. They are bound to distinct evolutive prognosis. The surgical excision is the treatment of choice which is rarely followed by recurrence. However, when the lesion is superficial and non aggressive and when the body site is adequate, topical applications of imiquimod can provoke the neoplastic regression. This type of immunotherapy brings 70 to 90% complete remission. A medical follow-up of the treated site is mandatory for a couple of years.
authors.affiliation: CHU du Sart Tilman, Service de Dermatopathologie, Liège.
authors.forename: C
authors.initials: C
authors.lastname: Piérard-Franchimont
authors.forename: A F
authors.initials: AF
authors.lastname: Nikkels
authors.forename: P
authors.initials: P
authors.lastname: Paquet
authors.forename: P
authors.initials: P
authors.lastname: Quatresooz
authors.forename: G E
authors.initials: GE
authors.lastname: Piérard
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000634:Aminoquinolines / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000077271:Imiquimod